Pre-Phase-2 Hipster Syndrome

For the connoisseur who was titrating triple agonists back when the molecule still went by a five-digit code.

Filed under Survodutide ·Ecnoglutide ·Orforglipron · #stack-life ·#glp-1 ·#cope

Active Compounds

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Ecnoglutide · GLP-1 Receptor Agonist

A biased-agonist GLP-1 receptor agonist from Sciwind Biosciences, engineered to favor Gs/cAMP signaling over β-arrestin recruitment. Phase 3 data in overweight/obese adults showed ~13.2% body weight reduction at 40 weeks. Approved or pending approval in China; not FDA-approved.

Orforglipron · Incretin Mimetic

Foundayo (orforglipron) is Eli Lilly's oral small-molecule GLP-1 receptor agonist. Phase 3 trials show up to 11.2% weight loss via daily pill — no injections required. Regulatory submissions expected 2026.

RX: Survodutide · Ecnoglutide · Orforglipron
Dosage: 0.5mg, hand-reconstituted, cited from a preprint
Half-life: until it hits r/PeptideVendors
Source: manual
Tags: stack-life , glp-1 , cope
Stamped: 2026-08-26 · Cycle 034
Lot #: LOT-20260826T13:26:06.739Z